| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss | -1,996 | -1,796 | -971 | -2,441 |
| Stock-based compensation | 370 | 245 | 115 | 325 |
| Depreciation and amortization | 148 | 96 | 39 | 129 |
| Amortization/accretion of investments | 54 | 37 | 19 | 76 |
| Loss on equity investments, net | -5 | -8 | -8 | -43 |
| Deferred income taxes | - | - | - | 0 |
| Other non-cash items | -50 | -36 | -2 | -6 |
| Accounts receivable, net | 703 | -310 | -280 | 672 |
| Prepaid expenses and other assets | 84 | 150 | -46 | 147 |
| Inventory | 213 | 122 | 8 | 208 |
| Right-of-use assets, operating leases | -28 | -19 | -9 | 63 |
| Accounts payable | -114 | -203 | -156 | -103 |
| Accrued liabilities | -196 | -395 | -381 | -415 |
| Deferred revenue | 108 | 68 | -29 | -177 |
| Income taxes payable | - | - | - | -58 |
| Operating lease liabilities | -15 | -10 | -5 | 33 |
| Other liabilities | -137 | -25 | 33 | -5 |
| Net cash used in operating activities | -2,803 | -1,956 | -1,037 | -3,829 |
| Purchases of marketable securities | 4,221 | 3,059 | 1,764 | 4,641 |
| Proceeds from maturities of marketable securities | 4,634 | 3,424 | 1,933 | 4,648 |
| Proceeds from sales of marketable securities | 1,744 | 1,059 | 688 | 3,010 |
| Purchases of property, plant and equipment | 153 | 120 | 117 | 529 |
| Acquisition of business, net of cash acquired | - | - | - | 0 |
| Investment in convertible notes and equity securities | - | - | - | 0 |
| Purchase of intangible asset | 10 | 10 | 10 | - |
| Net cash provided by investing activities | 1,994 | 1,294 | 730 | 2,488 |
| Proceeds from issuance of common stock through equity plans | 19 | 17 | 3 | 55 |
| Repurchase of common stock, including excise tax | - | - | - | 0 |
| Tax payments related to net share settlements on equity awards | 1 | 1 | 1 | - |
| Changes in financing lease liabilities | 6 | 3 | -2 | -4 |
| Net cash provided by financing activities | 12 | 13 | 4 | 59 |
| Effect of changes in exchange rates on cash and cash equivalents | 2 | 1 | - | 1 |
| Net decrease in cash, cash equivalents and restricted cash | -795 | -648 | -303 | -1,281 |
| Cash and cash equivalents at beginning of period | 1,929 | 1,929 | 1,929 | 2,928 |
| Cash and cash equivalents at end of period | 1,134 | 1,281 | 1,626 | 1,647 |
Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA)